TWIST1 Protein Expression in Plasma Cell Neoplasias and Plasmablastic Lymphoma

BACKGROUND. In malignant neoplasms, overexpression of transcription regulator TWIST1 is associated with high metastasis rate and spread of tumor cells as well as their evasion of apoptosis and chemoresistance occurrence. At present, there are essentially no data on TWIST1 protein expression in plasma cell neoplasias (PN) and plasmablastic lymphoma (PBL).

AIM. To determine the rate and pattern of TWIST1 expression based on the analysis of bone marrow core biopsy samples and biopsy samples of tumor substrate from patients with various PNs and PBLs as well as to compare TWIST1 expression with t(4;14)(p16;q32) and the mutation status of KRAS, NRAS, and BRAF genes.

MATERIALS & METHODS. The study enrolled 235 patients with various PNs aged 19–87 years (median 56 years) examined at the National Research Center for Hematology in the period of 2018–2025. Male/female ratio was 1.53:2 (102 men and 133 women). Distribution of patients according to the nosologies was as follows: monoclonal gammopathy of undetermined significance (MGUS; n = 28), smoldering myeloma (n = 31), multiple myeloma (n = 102), plasmacytoma (PM; n = 20), plasma cell leukemia (PCL; n = 19), and PBL (n = 35). Paraffin block sections of bone marrow core/tumor biopsy samples were histologically and immunohistochemically analyzed using anti-TWIST1 antibodies. KRAS and NRAS mutations in bone marrow CD138+ cells were detected by Sanger sequencing. The mutation profile of gene BRAFV600E was analyzed by allele-specific real-time PCR.

RESULTS. The proportion of TWIST1-positive plasma cells as well as the intensity and pattern of its expression considerably varied in PNs. The highest proportion of positive plasma cells was observed in PCL (0–30 %, median 4.4 %), PM (0–30 %, median 4.4 %), and PBL (0–15 %, median 4.9 %). Intense reaction also predominated in tissues from PM (12/20; 60 %) and PBL (25/35; 71.4 %) patients. Monomorphic reaction was typically detected in PCL (10/19; 52.6 %) and PBL (26/35; 74.3 %). The study demonstrated the potential of TWIST1 expression to be used as an additional criterion for MGUS diagnosis and for differential diagnosis of PBL and PN. No significant association of ТWIST1 expression with either t(4;14)(p16;q32) or mutation status of KRAS, NRAS, and BRAF was noted.

CONCLUSION. Immunohistochemical analysis of bone marrow core/tumor substrate biopsy samples with anti-TWIST1 antibodies can be used as an additional criterion for differential diagnosis of various PNs.

• Mariya Vladimirovna Melnikova National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167 https://orcid.org/0009-0003-1694-6861 (unauthenticated)
• A.M. Kovrigina National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167; IM Sechenov First Moscow State Medical University, 8 korp. 2 Trubetskaya ul., Moscow, Russian Federation, 119991 https://orcid.org/0000-0002-1082-8659 (unauthenticated)
• M.V. Soloveva National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167 https://orcid.org/0000-0003-4142-171X (unauthenticated)
• Yu.A. Chabaeva National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167 https://orcid.org/0000-0001-8044-598X (unauthenticated)
• S.M. Kulikov National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167 https://orcid.org/0000-0002-6288-7570 (unauthenticated)
• T.N. Obukhova National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167 https://orcid.org/0000-0003-1613-652X (unauthenticated)
• B.V. Biderman National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167 https://orcid.org/0000-0002-6253-3334 (unauthenticated)
• I.A. Yakutik National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167 https://orcid.org/0000-0002-5532-1122 (unauthenticated)
• A.B. Sudarikov National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167 https://orcid.org/0000-0001-9463-9187 (unauthenticated)

1. Pei H, Li Y, Liu M, Chen Y. Targeting Twist expression with small molecules. Medchemcomm. 2016;8(2):268–75. doi: 10.1039/c6md00561f. DOI: https://doi.org/10.1039/C6MD00561F
2. Wang T, Rho O, Eguiarte-Solomon F, DiGiovanni J. TWIST1 as a target for prevention of cutaneous squamous cell carcinoma. Mol Carcinog. 2023;62(1):62–76. doi: 10.1002/mc.23482. DOI: https://doi.org/10.1002/mc.23482
3. Simpson P. Maternal-Zygotic Gene Interactions during Formation of the Dorsoventral Pattern in Drosophila Embryos. Genetics. 1983;105(3):615–32. doi: 10.1093/genetics/105.3.615. DOI: https://doi.org/10.1093/genetics/105.3.615
4. Wang SM, Coljee VW, Pignolo RJ, et al. Cloning of the human twist gene: its expression is retained in adult mesodermally-derived tissues. Gene. 1997;187(1):83–92. doi: 10.1016/S0378-1119(96)00727-5. DOI: https://doi.org/10.1016/S0378-1119(96)00727-5
5. Bertol JW, Johnston S, Ahmed R, et al. TWIST1 interacts with β/δ-catenins during neural tube development and regulates fate transition in cranial neural crest cells. Development. 2022;149(15):dev200068. doi: 10.1242/dev.200068. DOI: https://doi.org/10.1242/dev.200068
6. Tseng JC, Chen HF, Wu KJ. A twist tale of cancer metastasis and tumor angiogenesis. Histol Histopathol. 2015;30(11):1283–94. doi: 10.14670/HH-11-638.
7. Qin Q, Xu Y, He T, et al. Normal and disease-related biological functions of TWIST1 and underlying molecular mechanisms. Cell Res. 2012;22(1):90–106. doi: 10.1038/cr.2011.144. DOI: https://doi.org/10.1038/cr.2011.144
8. Liu X, Ma Y, Li R, et al. Niche TWIST1 is critical for maintaining normal hematopoiesis and impeding leukemia progression. Haematologica. 2018;103(12):1969–79. doi: 10.3324/haematol.2018.190652. DOI: https://doi.org/10.3324/haematol.2018.190652
9. Norozi F, Ahmadzadeh A, Shahjahani M, et al. Twist as a new prognostic marker in hematological malignancies. Clin Transl Oncol. 2016;18(2):113–24. doi: 10.1007/s12094-015-1357-0. DOI: https://doi.org/10.1007/s12094-015-1357-0
10. Radhakrishnan K, Truong L, Carmichael CL. An “unexpected” role for EMT transcription factors in hematological development and malignancy. Front Immunol. 2023;14:1207360. doi: 10.3389/fimmu.2023.1207360. DOI: https://doi.org/10.3389/fimmu.2023.1207360
11. WHO Classification of Tumours Editorial Board. Haematolymphoid tumours. Lyon: IARC; 2024. (WHO classification of tumours series, 5th ed.; vol. 11). Available from: https://tumourclassification.iarc.who.int/chapters/63 (accessed 06.06.2025).
12. Cheong CM, Mrozik KM, Hewett DR, et al. Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma. Cancer Lett. 2020;475:99–108. doi: 10.1016/j.canlet.2020.01.040. DOI: https://doi.org/10.1016/j.canlet.2020.01.040
13. Hu Y, Chen W, Wang J. Progress in the identification of gene mutations involved in multiple myeloma. Onco Targets Ther. 2019;12:4075–80. doi: 10.2147/OTT.S205922. DOI: https://doi.org/10.2147/OTT.S205922
14. Mulligan G, Lichter DI, Di Bacco A, et al. Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood. 2014;123(5):632–9. doi: 10.1182/blood-2013-05-504340. DOI: https://doi.org/10.1182/blood-2013-05-504340
15. Сергеева А.М., Сурин В.Л., Чабаева Ю.А. и др. Мутации в генах KRAS/NRAS и эффективность индукционной терапии по трехкомпонентным схемам на основе бортезомиба у пациентов с впервые диагностированной множественной миеломой. Клиническая онкогематология. 2024;17(3):256–65. doi: 10.21320/2500-2139-2024-17-3-256-265. [Sergeeva A.M., Surin V.L., Chabaeva Yu.A., et al. KRAS/NRAS Gene Mutations and the Efficacy of Bortezomib-Based Triplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma. Clinical oncohematology. 2024;17(3):256–65. doi: 10.21320/2500-2139-2024-17-3-256-265. (In Russ)] DOI: https://doi.org/10.21320/2500-2139-2024-17-3-256-265
16. Мельникова М.В., Ковригина А.М., Соловьева М.В. Плазмобластная лимфома и плазмобластная миелома: диагностическая дилемма (обзор литературы). Клиническая онкогематология. 2024;17(2):129–40. doi: 10.21320/2500-2139-2024-17-2-129-140. [Melnikova M.V., Kovrigina A.M., Soloveva M.V. Plasmablastic Lymphoma and Plasmablastic Myeloma: А Diagnostic Dilemma (Literature Review). Clinical oncohematology. 2024;17(2):129–40. doi: 10.21320/2500-2139-2024-17-2-129-140. (In Russ)] DOI: https://doi.org/10.21320/2500-2139-2024-17-2-129-140
17. Менделеева Л.П., Соловьев М.В., Рехтина И.Г. и др. Клинические рекомендации Министерства здравоохранения Российской Федерации «Множественная миелома». Ассоциация онкологов России, Национальное гематологическое общество, Региональная общественная организация «Общество онкогематологов», 2024. (электронный документ) Доступно по: https://cr.minzdrav.gov.ru/preview-cr/144_2. Ссылка активна на 08.09.2025. [Mendeleeva L.P., Solovev M.V., Rekhtina I.G., et al. Clinical guidelines of the Ministry of Health of the Russian Federation “Multiple myeloma”. Russian Association of Oncologists, National Hematology Society, Regional Public Organization “Society of Oncohematology”. (Internet) Available from: https://cr.minzdrav.gov.ru/preview-cr/144_2. Accessed 08.09.2025. (In Russ)]
18. Clarke SE, Fuller KA, Erber WN. Chromosomal defects in multiple myeloma. Blood Rev. 2024;64:101168. doi: 10.1016/j.blre.2024.101168. DOI: https://doi.org/10.1016/j.blre.2024.101168
19. Hou Q, Li X, Ma H, et al. A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast. Sci Rep. 2025;15(1):2204. doi: 10.1038/s41598-024-83630-x. DOI: https://doi.org/10.1038/s41598-024-83630-x
20. Zhuge L, Lin X, Fan Z, et al. Global, regional and national epidemiological trends of multiple myeloma from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021. Front Public Health. 2025;13:1527198. doi: 10.3389/fpubh.2025.1527198. DOI: https://doi.org/10.3389/fpubh.2025.1527198
21. Maura F, Rajanna AR, Ziccheddu B, et al. Genomic Classification and Individualized Prognosis in Multiple Myeloma. J Clin Oncol. 2024;42(11):1229–40. doi: 10.1200/JCO.23.01277. DOI: https://doi.org/10.1200/JCO.23.01277
22. Zhao Z, Rahman MA, Chen ZG, et al. Multiple biological functions of TWIST1 in various cancers. Oncotarget. 2017;8(12):20380–93. doi: 10.18632/oncotarget.14608. DOI: https://doi.org/10.18632/oncotarget.14608
23. Ning X, Zhang K, Wu Q, et al. Emerging role of TWIST1 in fibrotic diseases. J Cell Mol Med. 2018;22(3):1383–91. doi: 10.1111/jcmm.13465. DOI: https://doi.org/10.1111/jcmm.13465
24. Wu YH, Huang YF, Chang TH, Chou CY. Activation of TWIST1 by COL11A1 promotes chemoresistance and inhibits apoptosis in ovarian cancer cells by modulating NF-κB-mediated IKKβ expression. Int J Cancer. 2017;141(11):2305–17. doi: 10.1002/ijc.30932. DOI: https://doi.org/10.1002/ijc.30932
25. Tran PT, Shroff EH, Burns TF, et al. TWIST1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis. PLoS Genet. 2012;8(5):e1002650. doi: 10.1371/journal.pgen.1002650. DOI: https://doi.org/10.1371/journal.pgen.1002650
26. Yang JZ, Lian WG, Sun LX, et al. High nuclear expression of TWIST1 in the skeletal extramedullary disease of myeloma patients predicts inferior survival. Pathol Res Pract. 2016;212(3):210–6. doi: 10.1016/j.prp.2015.12.011. DOI: https://doi.org/10.1016/j.prp.2015.12.011
27. Bourguignon LY, Wong G, Earle C, et al. Hyaluronan-CD44 interaction promotes c-Src-mediated twist signaling, microRNA-10b expression, and RhoA/RhoC up-regulation, leading to Rho-kinase-associated cytoskeleton activation and breast tumor cell invasion. J Biol Chem. 2010;285(47):36721–35. doi: 10.1074/jbc.M110.162305. DOI: https://doi.org/10.1074/jbc.M110.162305
28. Менделеева Л.П., Соловьев М.В., Рехтина И.Г. и др. Клинические рекомендации Министерства здравоохранения Российской Федерации «Плазмоклеточный лейкоз». Ассоциация онкологов России, Национальное гематологическое общество, Региональная общественная организация «Общество онкогематологов», 2024. (электронный документ) Доступно по: https://cr.minzdrav.gov.ru/preview-cr/808_1. Ссылка активна на 08.09.2025 г. [Mendeleeva L.P., Solovev M.V., Rekhtina I.G., et al. Clinical guidelines of the Ministry of Health of the Russian Federation “Plasma cell leukemia”. Russian Association of Oncologists, National Hematology Society, Regional Public Organization “Society of Oncohematology”. (Internet) Available from: https://cr.minzdrav.gov.ru/preview-cr/808_1. Accessed 08.09.2025. (In Russ)]
29. Heider M, Nickel K, Högner M, Bassermann F. Multiple Myeloma: Molecular Pathogenesis and Disease Evolution. Oncol Res Treat. 2021;44(12):672–81. doi: 10.1159/000520312. DOI: https://doi.org/10.1159/000520312
30. Rebmann Chigrinova E, Porret NA, Andres M, et al. Correlation of plasma cell assessment by phenotypic methods and molecular profiles by NGS in patients with plasma cell dyscrasias. BMC Med Genomics. 2022;15(1):203. doi: 10.1186/s12920-022-01346-1. DOI: https://doi.org/10.1186/s12920-022-01346-1